Hikma Pharmaceuticals Plc Notice to Bondholders (9536C)
22 Ottobre 2020 - 2:16PM
UK Regulatory
TIDMHIK
RNS Number : 9536C
Hikma Pharmaceuticals Plc
22 October 2020
London, October 22, 2020
Hikma Finance USA LLC (the "Issuer")
Notice to the holders of the US$500,000,000 3.250 per cent.
Guaranteed Notes due 2025 (the "Notes")
The Issuer refers to the terms and conditions of the Notes (the
"Conditions") set out in the offering circular dated 7 July 2020.
Capitalised terms used in this notice and not defined herein shall
have the meaning set out in the Conditions.
Fitch Ratings has today announced that it has assigned Hikma
Pharmaceuticals Plc (Hikma, Company) a 'BBB-' first-time Long-Term
Issuer Default Rating (outlook: Stable). Hikma's existing rating of
BBB- (outlook: Stable) from S&P remains unchanged, and
accordingly the Company has achieved investment grade status from
two rating agencies in accordance with the Conditions.
The Company's obligations under Condition 5.2 (Limitation on
Indebtedness) and Condition 5.4 (Guarantor Group) of the Terms and
Conditions of the Notes have therefore been suspended with effect
from 22 October 2020, and shall remain suspended for so long as the
Company retains its investment grade status, all in accordance with
the Conditions.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal +44 (0)20 7399 2760/ +44 7776
EVP, Strategic Planning and Global Affairs 477050
uk-investors@hikma.uk.com
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P,
BBB-/stable Fitch and Ba1/stable Moody's)
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com
(c)2020 Hikma Pharmaceuticals PLC. All rights reserved.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DOCUUAURRUURUAA
(END) Dow Jones Newswires
October 22, 2020 08:16 ET (12:16 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024